Vaginal Microbiome Research Consortium for Africa

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-15

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To characterise vaginal microbial community dynamics (bacterial and fungal) from different geographies in Africa to understand the microbial diversity that occurs in women with stable L. crispatus-dominant versus unstable vaginal microbiota.
2. To identify vaginal communities associated with low levels of inflammation in women from different geographies in Africa
3. To examine prevalence and diversity of HPV types circulating in the different geographies and their interaction with the vaginal microbiota
4. To create a biobank of stored samples that can be used in future studies and for the isolation of regionally representative bacterial strains.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rwanda Vaginal Microbiota Restoration Study

NCT02459665

Bacterial Vaginosis

COMPLETED NA

Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology

NCT02527941

Bacterial Vaginosis HIV Infections

COMPLETED PHASE1

Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi

NCT00140764

Bacterial Vaginosis Trichomonas Vaginitis Urogenital Diseases

COMPLETED PHASE3

Vaginal Ecosystem and Network in the United States Study

NCT06472765

Bacterial Vaginosis Candidiasis Urinary Tract Infections +8 more

ENROLLING_BY_INVITATION

Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women

NCT02272231

Vaginosis, Bacterial

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This investment forms part of the BMGF Calestous Juma Scientific Leadership (CJSL) Fellowship to Dr Jo-Ann Passmore, to pilot VMRC4Africa and establish a collaborative regional network with African partners and Centres of Excellence with capacity and expertise to conduct clinical trials and vaginal microbiome research in Africa. With this CJSL Fellowship investment, Dr Passmore and her collaborators aim to enrol parallel cohorts of women from two sites in two African countries (South Africa: Desmond Tutu HIV Foundation \[DTHF\] and Kenya Medical Research Institute \[KEMRI\]) to evaluate detailed temporal fluctuations in vaginal microbiota in young, generally healthy women from Southern and Eastern Africa. These parallel cohorts will be intensively followed for 10 weeks, to create detailed profiles of vaginal microbial community state types (CSTs; by 16S rRNA gene sequencing) and fungal communities \[by internal transcribed spacer (ITS) sequencing\], to identify women with stable Lactobacillus-dominated microbiota, with no evidence of genital inflammation. Through the establishment of an "African vaginal microbiome biorepository", the intention will be to create a biobank from which to ultimately select geographically diverse Lactobacillus crispatus strains with health promoting characteristics that can be co-formulated into live biotherapeutic products (LBPs) to treat bacterial vaginosis (BV) for women globally.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy

Cervicovaginal microbiota, mycobiota, and HPV prevalence, and identify women with stable Lactobacillus-dominated microbiota, with no STIs and no evidence of genital inflammation.

None - observational study only

Intervention Type DIAGNOSTIC_TEST

No interventions, diagnostics tests for HIV, pregnancy, STIs and BV only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

None - observational study only

No interventions, diagnostics tests for HIV, pregnancy, STIs and BV only

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female at birth
* Willing and able to provide informed consent for screening and cognitive ability to understand sampling procedures
* Not pregnant
* HIV negative on testing performed by study staff
* 18-40 years old
* Planning to stay in the area for the next 10 weeks
* Able and willing to provide adequate locator information for study retention purposes
* Willing and able to return for all 3 nurse visits and return self-swabs to the clinic weekly
* Sexually active for the last 3 months defined as penetrative penile-vaginal intercourse at least once in the last 3 months

Exclusion Criteria

* Male at birth
* Not willing to provide consent
* Pregnant or actively trying to conceive/become pregnant in the next 10 weeks
* Living with HIV or untreated STIs (CT, NG, TV) or bacterial vaginosis (Nugent \> 3)
* Currently taking antibiotics or having been on antibiotic treatment in the previous four weeks
* \<18 or \>40 years old
* On chronic disease management for gynaecological conditions
* Any medical condition or other factors which would preclude study participation as per principal Investigator's or designee's decision, including but not limited to cancer of the cervix
* Any mental health condition which, in the opinion of the investigator, would preclude comprehension of informed consent, or preclude study participation
* Currently enrolled on any other study prohibiting co-enrolment

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes